Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Short Interest Up 310.3% in January

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) saw a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 693,000 shares, an increase of 310.3% from the December 31st total of 168,900 shares. Based on an average daily trading volume, of 3,270,000 shares, the short-interest ratio is currently 0.2 days.

Insider Buying and Selling

In other news, Director Anthony James Culverwell purchased 100,000 shares of the business’s stock in a transaction on Monday, December 23rd. The stock was purchased at an average cost of $0.45 per share, with a total value of $45,000.00. Following the acquisition, the director now directly owns 100,317 shares in the company, valued at approximately $45,142.65. This trade represents a 31,545.74 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Gordon Dunn purchased 122,221 shares of the business’s stock in a transaction on Monday, December 23rd. The stock was purchased at an average cost of $0.45 per share, with a total value of $54,999.45. Following the completion of the acquisition, the chief financial officer now owns 151,077 shares in the company, valued at approximately $67,984.65. This trade represents a 423.55 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 777,777 shares of company stock valued at $350,000. Company insiders own 3.70% of the company’s stock.

Hedge Funds Weigh In On Quoin Pharmaceuticals

An institutional investor recently bought a new position in Quoin Pharmaceuticals stock. Apollon Wealth Management LLC acquired a new stake in Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 80,025 shares of the company’s stock, valued at approximately $52,000. Apollon Wealth Management LLC owned 1.58% of Quoin Pharmaceuticals at the end of the most recent quarter. 8.63% of the stock is owned by hedge funds and other institutional investors.

Quoin Pharmaceuticals Trading Down 6.2 %

Shares of Quoin Pharmaceuticals stock traded down $0.02 on Tuesday, hitting $0.32. 1,683,802 shares of the company traded hands, compared to its average volume of 4,501,940. The firm’s 50-day simple moving average is $0.62 and its 200 day simple moving average is $0.62. The company has a market cap of $1.62 million, a P/E ratio of -0.08 and a beta of 1.75. Quoin Pharmaceuticals has a 12-month low of $0.31 and a 12-month high of $6.18.

Quoin Pharmaceuticals (NASDAQ:QNRX) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.03). During the same quarter in the previous year, the firm posted ($1.95) EPS. Analysts predict that Quoin Pharmaceuticals will post -2.05 earnings per share for the current year.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.